Bernstein Liebhard LLP Investigates Claims on Behalf of Shareholders of Teva Pharmaceuticals Industries, Ltd.

Feb. 8, 2017

Bernstein Liebhard LLP is investigating whether the Board of Directors of Teva Pharmaceuticals Industries, Ltd. (“Teva” or the “Company”) (NYSE: TEVA) breached their fiduciary duties to the Company’s shareholders.

On February 7, 2017, amid reports of a bribery investigation, Teva announced that its Chief Executive Officer Erez Vigodman will resign.  Teva shares fell approximately 6% on this adverse news.

If you are interested in discussing your rights as a Teva shareholder, and/or have information relating to the matter, please contact Joseph R. Seidman, Jr. at (877) 779-1414 or seidman@bernlieb.com.

Bernstein Liebhard LLP has pursued hundreds of securities, consumer and shareholder rights cases and recovered over $3.5 billion for its clients.  The Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times.